Skip to main content

Site notifications

ELIGARD (Mundipharma Pty Ltd)

Product name
ELIGARD
Date registered
Evaluation commenced
Decision date
Approval time
204 (255 working days)
Active ingredients
Leuprorelin acetate
Registration type
EOI
Indication

ELIGARD 45mg 6 month is now also indicated for the treatment of children 2 years of age and older with central precocious puberty (CPP).

Help us improve the Therapeutic Goods Administration site